Elanix Biotechnologies

Elanix Biotechnologies develops and commercializes tissue regeneration products for chronic and acute wound care, and advanced skin care products for dermatological and gynaecological applications. Our technology is the result of 30 years of progenitor cell research and development by Prof. Lee Ann Laurent-Applegate and her team at the University Hospital of Lausanne (CHUV).The Company is headquartered in Berlin, Germany with offices in Nyon, Switzerland and Wiesbaden, Germany, and listed on the Frankfurt stock exchange under the symbol ELN.